Personalized Cancer Treatment Industry Outlook 2025-2029: Market Set to Cross $303 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Personalized Cancer Treatment Market Size By 2025?
The market size of personalized cancer treatment has been expanding swiftly in the past few years. It is projected to increase from $181.55 billion in 2024 to $201.57 billion in 2025, representing a compound annual growth rate (CAGR) of 11.0%. Factors such as the progress in genomics and molecular biology, the escalating occurrence of cancer, the broadening acceptance of personalized medicine, heightened consciousness about options for cancer treatment, and enhancements in cancer diagnostic and surveillance technologies have contributed to this historical growth.

How Big Is the Personalized Cancer Treatment Market Size Expected to Grow by 2029?
The market for personalized cancer treatments is projected to experience significant expansion in the coming years, expected to reach a value of $303.01 billion in 2029, with a compound annual growth rate (CAGR) of 10.7%. The enlargement during the forecast period can be ascribed to factors such as the proliferation of targeted therapies, sophisticated developments in AI and machine learning for strategic treatment planning, the surge of investments in oncological studies, the increasing requisition for precision medication, and the inception of innovative biomarkers for custom-tailored treatments. Key projections for this time frame include a growing reliance on combination therapies, an amplified integration of digital healthcare technologies, a rise in employing liquid biopsy techniques, the broadening of immunotherapy alternatives, and an intensified emphasis on patient-oriented healthcare models.

View the full report here:
https://www.thebusinessresearchcompany.com/report/personalized-cancer-treatment-global-market-report

Which Key Market Drivers Powering Personalized Cancer Treatment Market Expansion and Growth?
The escalating incidence of cancer is predicted to boost the expansion of the personalized cancer treatment market in the future. The surge in cancer cases is chiefly due to a rise in life expectancy, causing an increase in the number of people reaching an age more susceptible to cancer and an increased exposure to risk factors such as tobacco, alcohol, and obesity. Individualized cancer treatments offer targeted and efficient therapies to handle varied cancer types and stages, and this escalating burden kindles investment and innovation in precision medicine, with the objective to enhance patient outcomes via tailor-made treatment plans. For example, in February 2024, the World Health Organization, a Switzerland-based agency of the United Nations dedicated to global health and safety, forecasted that the global cancer burden is set to rise sharply, with an expected 77% increase in new cancer instances, hitting over 35 million by 2050, a significant leap from 20 million in 2022. Thus, the escalating incidence of cancer is fuelling the expansion of the personalized cancer treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19135&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Personalized Cancer Treatment Market?
Top firms in the personalized cancer treatment market are concentrating on creating novel solutions such as AI-powered multimodal immune profile algorithmic tests. These tests are designed to predict how patients will respond to immunotherapy and thus aid in the improvement of individual treatment strategies. This AI-enabled test evaluates various data types, including genomic, transcriptomic, and clinical biomarkers, to gauge a patient's immune profile and anticipate their reaction to immunotherapy. This helps categorize patients and drive personalized cancer therapies. For example, Tempus AI, Inc., a healthcare technology company based in the US, launched its first product in the immunotherapy diagnostic field, an AI-powered multimodal immune profile algorithmic test (IPS), in July 2024. This test, currently for research use only (RUO), measures various immunotherapy-connected biomarkers to generate a score that aids in predicting patient response to immunotherapy, thereby assisting personalized cancer treatment. These AI-based diagnostics for immunotherapy enhance patient classification and treatment choice in cancer care.

What Are the Emerging Segments in the Personalized Cancer Treatment Market?
The personalized cancer treatmentmarket covered in this report is segmented -

1) By Treatment Type: Targeted Therapy, Immunotherapy, Hormone Therapy, Chemotherapy, Radiation Therapy, Other Treatment Type
2) By Diagnostic Techniques: Genomic Sequencing, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, Biomarker Testing, Other Diagnostic Techniques
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Cancer Types
4) By End-Users: Hospitals And Clinics, Research Institutes, Other End Users

Subsegments:
1) By Targeted Therapy: Monoclonal Antibodies, Small Molecule Inhibitors, Angiogenesis Inhibitors, Signal Transduction Inhibitors
2) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines, Monoclonal Antibodies For Immunotherapy
3) By Hormone Therapy: Anti-Estrogens, Aromatase Inhibitors, Progestins, LHRH Agonists
4) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Taxanes
5) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radioimmunotherapy, Stereotactic Radiosurgery (SRS)
6) By Other Treatment Types: Gene Therapy, Stem Cell Transplantation, Metabolic Therapy, Nanomedicine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19135&type=smp

Who Are the Global Leaders in the Personalized Cancer Treatment Market?
Major companies operating in the personalized cancer treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche, Merck & Co. Inc., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, BioNTech SE, Illumina Inc., Artera, Exact Sciences Corporation., Moffitt Cancer Center, Myriad Genetics, NeoGenomics Laboratories, Guardant Health, Caris Life Sciences, Tempus AI Inc., Foundation Medicine, Immatics, Fate Therapeutics, CureVac AG, TScan Therapeutics, CureMetrix, PDC*line Pharma

Which are the Top Profitable Regional Markets for the Personalized Cancer Treatment Industry?
North America was the largest region in the personalized cancer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19135

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.